



Figure 1

Malignant Breast 96102003G H9C65



Malignant Breast 9609C033R H9C65



Normal Breast. 9712C030G H9C65



MB8 Cell Line H9C65






Figure 2


Malignant Breast 96102003G H95C30



Malignant Breast 9609C033R H95C30



Normal Breast 9712C030G H95C30



MB8 Cell Line H95C30




Figure 3

009552660




Figure 4

09550101-2055/660





Figure 5

00975501TOTOT*2055/660







Figure 6

095507-2055/660



Polyclonal Antisera, 1:5000



Monoclonal Antibodies 1:50

Figure 6 (cont'd)

TOTOT 20552660




Figure 7

0975502 10101




Figure 8

TOTOT"20552660




Figure 9

TOTOT 2055/660




Figure 10

09975501-101101






Figure 11

TOTOT 20552660




anti-BU101.3, 10923, 1:5000
sample reduced and boiled




anti-MAM.1, 10931, 1:5000
sample reduced and boiled

20552660



Polyclonal Antibody 10923
anti-BU101.3



Polyclonal Antibody 10931
anti-MAM.1

Figure 13

TTTTT 20552660




Figure 14

TOTOT 2055/660




Figure 15

FIGURE 16

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys
Cys
1 5 10 15
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu
Leu
20 25 30
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala
Lys
35 40 45
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys
Arg
50 55 60
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu
Val
65 70 75
80
Leu Val Lys Ile Leu Lys Lys Cys Ser Val
85 90

NOT FOR PUBLICATION

FIGURE 17

Assembly of BS106 from Individual Expressed Tags




Figure 18A

>BS106 consensus

CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCTGATCTTCAGGTCACCACC A
TGAAGTTCTTAGCAGTCCTGGTACTCTTGGGAGTTTCCATCTTTCTGGTCTCTGCCCAGAATCC
GACAAACAGCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGATGAAGCCCCTGA
TGCTGAAACCACTGCTGCTGCAACCACTGCGACCAC TGCTGCTCCTACCACTGCAACCACCGC
TGCTTCTACCACTGCTCGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCGAAT
GGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTGCAATTGGTCACAACCTATTCAT
GCTTCCTGTGATTTTCATCCAACCTACTTACCTTGCTACGATATCCCCTTTATCTCTAATCAGTTT
ATTTTCTTCAAATAAAAAATAACTATGAGCAACATA AAAAAAAAAAAAA

Figure 18B

>BS106 translation

MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAATTATTAAPTTATTAA
STTARKDIPVLPKWVGDLPNGRVCP

Figure 19A




Figure 19B





Figure 19C



Figures 20 A-D




Figure 21

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mammaglobin	CK19	
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
ER	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
PR	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
HER2	-0.12 (NS)	0.36 (p=0.003)	0.11 (NS)	0.02 (NS)	N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)	N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. **NS= not significant**